Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Tirzepatide

A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

Eli Lilly · Phase 2 · Completed · Enrollment 392

NCT06373146

ArmPopulationDoseWeeksEstimandWeight change
Tirzepatide (TZP) + Mibavademab (MIBA) [Group A]Obesity or overweightn/r24n/rn/r
TZP + Mibavademab-placebo (MIBA-PBO) [Group B]Obesity or overweightn/r24n/rn/r
TZP + MIBA then Tirzepatide-placebo (TZP-PBO) + MIBA [Group C]Obesity or overweightn/r24n/rn/r
TZP + MIBA [Group D]Obesity or overweightn/r24n/rn/r
TZP + MIBA-PBO [Group E]Obesity or overweightn/r24n/rn/r
TZP + MIBA-PBO then TZP-PBO + MIBA [Group F]Obesity or overweightn/r24n/rn/r
TZP + MIBA-PBO then TZP + MIBA [Group G]Obesity or overweightn/r24n/rn/r
TZP + MIBA-PBO then TZP-PBO + MIBA-PBO [Group H]Obesity or overweightn/r24n/rn/r